Chroma Drugs Secures $135M in Sequence B Financing to Advance Breakthrough Epigenetic Modifying Expertise and Develop Pipeline of Sturdy Precision Genomic

Funding to progress Chroma’s single-dose epigenetic modifying therapies and help growth of novel genetic medication platform designed to allow exact gene regulation whereas preserving genomic integrity Financing led by GV, with participation from ARCH Enterprise Companions, DCVC Bio, Mubadala Capital, Sixth Road, and all current buyers CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ — Chroma Drugs, Inc., […]